Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03945773
Title Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors (CaboPoint)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ipsen
Indications
Therapies
Age Groups: adult | senior
Covered Countries NLD | GBR | FRA | ESP | DEU | AUT


No variant requirements are available.